Recombinant var2csa and use thereof in detection of oncofetal chondroitin sulfate proteoglycan

A recombinant VAR2CSA with high CSA affinity addresses the need for early detection and monitoring of tumors by enabling effective detection and prognosis prediction of tumors expressing CSA.

HK40134749APending Publication Date: 2026-07-10SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)
Filing Date
2026-04-30
Publication Date
2026-07-10

AI Technical Summary

Technical Problem

Current methods lack effective tools for the early detection, diagnosis, and monitoring of tumors expressing chondroitin sulfate A (CSA), particularly for identifying specific subtypes of tumor-type chondroitin sulfate proteoglycans.

Method used

Development of a recombinant VAR2CSA with high binding affinity to chondroitin sulfate A (CSA) for the detection of tumor-type chondroitin sulfate and its modified proteoglycans, enabling early screening, diagnosis, and prognosis prediction of tumors.

Benefits of technology

The recombinant VAR2CSA effectively detects and monitors tumors expressing CSA, facilitating early detection and prognosis prediction.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and relates to a recombinant VAR2CSA, which can be used for detecting specific types of tumor-type chondroitin sulfate (ofCS) and proteoglycan (ofCSPG) modified by the tumor-type chondroitin sulfate (ofCS). The recombinant VAR2CSA disclosed by the invention has relatively high binding affinity with chondroitin sulfate A (CSA), and the tumor type chondroitin sulfate constructed by the recombinant VAR2CSA disclosed by the invention and a detection method of proteoglycan modified by the tumor type chondroitin sulfate have a detection effect on all malignant tumors expressing the CSA. The tumor-type chondroitin sulfate based on the recombinant VAR2CSA and a detection method of proteoglycan modified by the tumor-type chondroitin sulfate can be used for early screening and diagnosis of tumors, tumor load monitoring and prognosis prediction.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202380084316.0 (22) Application Date 2023.12.11 (66) Domestic Priority Data 202211578445.9 2022.12.09 CN (85) PCT International Application Entering National Phase Date 2025.06.06 (86) PCT International Application Application Data PCT / CN2023 / 137974 2023.12.11 (87) PCT International Application Publication Data WO2024 / 120537 ZH 2024.06.13 (71) Applicant: Sun Yat-sen University Cancer Center (Sun Yat-sen University Affiliated Cancer Hospital, Sun Yat-sen University Cancer Institute) Address: 510060 No. 651, Dongfeng East Road, Guangzhou, Guangdong Province (72) Inventors: Jia Weihua, Zhang Peifen, Wu Ziyi, Zhang Wenbin, He Yongqiao, Mu Quankai (74) Patent Agency: Beijing Wanhuida Law Firm 11111 Patent Attorneys: Xie Minnan, He Yingqian (51) Int.Cl. C07K 14 / 445 (2006.01) C12N 15 / 30 (2006.01) C12N 15 / 70 (2006.01) C12N 1 / 21 (2006.01) G01N 33 / 574 (2006.01) (54) Invention Title: A Recombinant VAR2CSA and Its Application in the Detection of Tumor-Type Chondroitin Sulfate Proteoglycans (57) Abstract: This disclosure belongs to the field of biomedicine and relates to a recombinant VAR2CSA, which can detect specific subtypes of tumor-type chondroitin sulfate (ofCS) and its modified proteoglycans (ofCSPG). The recombinant VAR2CSA of this disclosure has a high binding affinity to chondroitin sulfate A (CSA). The detection method for tumor-type chondroitin sulfate and its modified proteoglycans constructed using the recombinant VAR2CSA of this disclosure has the effect of detecting all malignant tumors expressing CSA. The detection method for tumor-type chondroitin sulfate and its modified proteoglycans based on the recombinant VAR2CSA of this disclosure can be used for early screening, diagnosis, tumor burden monitoring and prognosis prediction of tumors. CN 120897926 A 2025.11.04 CN 1 20 89 79 26 A